Neuro-Complex & Multi Supplements for Migraine Prevention
Eligible age
18–75 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this prospective, monocentric, open-label, non-randomized and single arm study is to evaluate a reduction of migraine days per months (MDM) by 25% by using the combined supplementation with Neuro-Complex \& Multi after 8 weeks of product intake on participants with diagnosis of migraine meeting the criteria of the International Classification of Headache Disorders (ICHD-3) (with or without aura). The main endpoint of this clinical trial is : The mean changes in migraine days per month (MDM) after 8 weeks of supplementation. Participants will: Orally consume two caps of each product (taken at the same time) daily, one in the morning and one at the lunchtime preferably during meal, for 8 weeks after a running period of 8 weeks without supplementation. Intake will be initiated from the day of follow-up visit (V1) after all study procedures being performed until the day of the end-of-study visit (V2).
Sponsor: Benfida, a department of Handi-Move
You may qualify if…
- ✓ Male or female between 18 and 75 years;
- ✓ Diagnosis of migraine meeting the criteria of the International Classification of Headache Disorders (ICHD-3) (with or without aura)
- ✓ At least 5 attacks fulfilling the criteria below
- ✓ Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
- ✓ Headache has at least two of the following characteristics
- ✓ unilateral location
- ✓ pulsating quality
- ✓ moderate or severe pain intensity
You may not qualify if…
- ✕ Other primary head pain disorders such as but not restricted to tension-type headache, cluster headache, fibromyalgia;
- ✕ Secondary head pain due to trauma, injury, infections;
- ✕ Medication overuse for headache defined as acute headache medication \>10-15 days per month depending on the half-life of the medication (left to PI discretion);
- ✕ Severe medical conditions affecting absorption and metabolism of the product, including but not restricted to chronic use of laxatives;
- ✕ Bariatric surgery;
- ✕ Severe psychiatric conditions that could interfere with diary compliance or assessment of the product (e.g., severe depression or cognitive impairments) left to investigator discretion;
- ✕ Use of other dietary supplements that could potentially affect migraines, unless willing to discontinue them before the study begins (wash out period of 3 months);
- ✕ Women who are pregnant, breastfeeding, or planning to become pregnant during the study period;
Source: ClinicalTrials.gov · NCT07015411 · last updated 2025-06-11